-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Since August, financing in the domestic pharmaceutical and medical health fields has been ho.
According to incomplete statistics in the industry, from August 1 to August 7, a total of 42 investment and financing events in the domestic medical and health field occurre.
Judging from the amount disclosed in a single transaction, many of them have a financing amount of more than 100 million US dollars, such as Taiban.
Biotech received US$300 million in strategic financing, and Viterilon received US$200 million in Series B financin.
It is worth noting that in the past week, another group of pharmaceutical companies announced the completion of financin.
On August 15, Jiangsu Baisaifei Biotechnology C.
, Lt.
(hereinafter referred to as "Baisaifei") officially announced the completion of tens of millions of B+ rounds of financin.
This round of financing was led by the strategic investor Yuansheng Venture Capital, followed by Navigation New Territorie.
It is understood that this round of financing will further promote Baisaifei to build a biomaterial surface modification technology platform for healthy life, increase efforts to attract and cultivate high-level R&D talents, and continue to invest in expanding R&D sites, supplement R&D equipment, and build high-end R&D personne.
A customized R&D platform for horizontal products, an inspection and testing center, and a regulatory science base to promote the construction of upstream key raw material industry clusters for medical devices, fully empower the localization process of high-end medical devices, and fill the gaps in the field of domestic independent research and development products; continue to develop high-value products Surface modification technology development and product transformation in the field of life science consumables, solving industry pain point.
.
On August 11, Insilicon announced that it has received D+ round of financin.
This round of financing was funded by Saudi Aramco's diversified venture capital fund Prosperity7 Ventures lea.
After this round of financing, a total of 95 million US dollars of Series D financing has been complete.
The participating investors include many professional investors in the field of biomedicine and life sciences around the world, including Boston Investment, Warburg Pincus, Bohai Huamei (Shanghai) Equity Investment Fund, Qiming Ventures, Deerfield, Lanting Investment,et.
According to the announcement, after the newly raised D round of financing, in addition to further supporting Insilicon in biomedicine, it will also be used for Insilico's key strategic layout, including the further development of its end-to-end artificial intelligence drug research and development platform Pharm.
AI; promote the construction of fully automated intelligent robot drug research and development laboratories and robot biodata factories; and support the construction of Insilicon's regional centers around the worl.
It was reported on August 11 that Wuhan Baiyingnuo Biotechnology C.
, Lt.
(hereinafter referred to as "Baiyingnuo Technology") has also completed tens of millions of seed round financin.
This financing was jointly invested by Dongke Chuangxing and Wuhan Institute of Biotechnolog.
.According to the data, Baiyingnuo Technology was established in June 2021 and is a provider of immunotherapy and diagnosis services for advanced tumor.
It has been working on the screening and verification of new cancer immunotherapy sites, preclinical research on antibody drugs and cell therapy drugs, and while providing immunotherapy diagnosis and services in the middle and late stages of tumors, it is also actively deploying peptide drug research and developmen.
The funds obtained from this financing will be used to promote the research and development and registration inspection of various product pipelines of Bioinno Technology, so as to accelerate the launch of product pipelines and the acquisition of IND clinical approval document.
In general, most investment and financing projects in the fields of medicine and medical health are still focused on innovative drugs, innovative medical devices, and corporate services such as CRO and CDM.
In this regard, the industry believes that behind the frequent investment and financing of these tracks is that the market prospects of these industries are widely optimistic by investors for a long tim.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
According to incomplete statistics in the industry, from August 1 to August 7, a total of 42 investment and financing events in the domestic medical and health field occurre.
Judging from the amount disclosed in a single transaction, many of them have a financing amount of more than 100 million US dollars, such as Taiban.
Biotech received US$300 million in strategic financing, and Viterilon received US$200 million in Series B financin.
It is worth noting that in the past week, another group of pharmaceutical companies announced the completion of financin.
On August 15, Jiangsu Baisaifei Biotechnology C.
, Lt.
(hereinafter referred to as "Baisaifei") officially announced the completion of tens of millions of B+ rounds of financin.
This round of financing was led by the strategic investor Yuansheng Venture Capital, followed by Navigation New Territorie.
It is understood that this round of financing will further promote Baisaifei to build a biomaterial surface modification technology platform for healthy life, increase efforts to attract and cultivate high-level R&D talents, and continue to invest in expanding R&D sites, supplement R&D equipment, and build high-end R&D personne.
A customized R&D platform for horizontal products, an inspection and testing center, and a regulatory science base to promote the construction of upstream key raw material industry clusters for medical devices, fully empower the localization process of high-end medical devices, and fill the gaps in the field of domestic independent research and development products; continue to develop high-value products Surface modification technology development and product transformation in the field of life science consumables, solving industry pain point.
.
On August 11, Insilicon announced that it has received D+ round of financin.
This round of financing was funded by Saudi Aramco's diversified venture capital fund Prosperity7 Ventures lea.
After this round of financing, a total of 95 million US dollars of Series D financing has been complete.
The participating investors include many professional investors in the field of biomedicine and life sciences around the world, including Boston Investment, Warburg Pincus, Bohai Huamei (Shanghai) Equity Investment Fund, Qiming Ventures, Deerfield, Lanting Investment,et.
According to the announcement, after the newly raised D round of financing, in addition to further supporting Insilicon in biomedicine, it will also be used for Insilico's key strategic layout, including the further development of its end-to-end artificial intelligence drug research and development platform Pharm.
AI; promote the construction of fully automated intelligent robot drug research and development laboratories and robot biodata factories; and support the construction of Insilicon's regional centers around the worl.
It was reported on August 11 that Wuhan Baiyingnuo Biotechnology C.
, Lt.
(hereinafter referred to as "Baiyingnuo Technology") has also completed tens of millions of seed round financin.
This financing was jointly invested by Dongke Chuangxing and Wuhan Institute of Biotechnolog.
.According to the data, Baiyingnuo Technology was established in June 2021 and is a provider of immunotherapy and diagnosis services for advanced tumor.
It has been working on the screening and verification of new cancer immunotherapy sites, preclinical research on antibody drugs and cell therapy drugs, and while providing immunotherapy diagnosis and services in the middle and late stages of tumors, it is also actively deploying peptide drug research and developmen.
The funds obtained from this financing will be used to promote the research and development and registration inspection of various product pipelines of Bioinno Technology, so as to accelerate the launch of product pipelines and the acquisition of IND clinical approval document.
In general, most investment and financing projects in the fields of medicine and medical health are still focused on innovative drugs, innovative medical devices, and corporate services such as CRO and CDM.
In this regard, the industry believes that behind the frequent investment and financing of these tracks is that the market prospects of these industries are widely optimistic by investors for a long tim.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
